Activation of the Poly(ADP-Ribose) Polymerase Pathway in Human Heart Failure

Table 1 Summary of the pretransplant data and drug therapy for the patients

Case No.	Status	NYHA	Diagnosis	Age	Sex	Digoxin	ACE	Diuretics	Dobutamine/Dopamine	Syncumar	Other	Cause of death
1	Failing	IV	CAD	40	F			+	+		Salicylate, antidepressant, antiarrhythmic drug (class III), proton pump inhibitor, vasodilatator, heparin, lipid lowering	—
2	Failing	IV	HCM	49	M		+			+	β-blocker, H2-receptor blocker, lipid lowering	—
3	Failing	IV	DCM	54	M	+	+	+			β-blocker, H2-receptor blocker, NSAID	—
4	Failing	IV	CAD	49	F		+	+		+	Calcium channel antagonist, β-blocker, antidepressant	—
5	Failing	IV	DCM	50	M		+	+		+	β-blocker, antiarrhythmic drug (class III), antidepressant	—
6	Failing	IV	CAD	48	F		+	+		+	β-blocker, Ca/Mg supplements, anti-anginal drug	—
7	Failing	lll–IV	DCM	49	M	+		+		+	—	—
8	Failing	IV	DCM	49	M			+		+	—	—
1	Donor			46	M			+	+		—	Ischemic stroke
2	Donor			56	M				+		—	Stroke
3	Donor			18	F			+	+		—	Trauma
4	Donor			37	F							Subarachnoid hemorrhage (stroke)
5	Donor			39	F				+			Apoplexia cerebri (stroke)

DCM indicates dilatative cardiomyopathy; HCM, hypertrophic cardiomyopathy; CAD, coronary artery disease; NYHA, class of failing according to the New York Heart Association; ACE-I, angiotensin convertase enzyme inhibitor.

ISSN: 1528-3658